Jake Leach

speaker

301 appearances 1 recordings 1 series first heard Feb 2026 last heard 19 Feb

Jake Leach’s voice in public audio — every appearance, attributed to the second.

Trend

recordings per month · last 12 months

Recordings per month over the last 12 months — 1 in all, peaking in Feb 2026 with 1.

Appearances

newest first · ▶ plays the moment

Vanguards of Healthcare by Bloomberg Intelligence · Dexcom Aims to Expand CGM Benefits to All Diabetic Patients and Beyond · 19 Feb 2026 podcast

There's a number of technologies that are going into G8 that have been under development for multiple decades.

And we finally got to the point now where we're ready to introduce them commercially.

And so we're going to share more of that this year as we kind of go out throughout the year in terms of what exactly G8 is.

But what you can count on is

It's going to be the smallest sensor wearable.

It's going to be the most accurate and most reliable wearable.

And it's going to be the software experience around it is going to be a whole new innovation around how CGMs work for a much broader use of patients.

We talked a little bit about how G7 is starting to be used by a very broad population of users.

G8 is going to continue to broaden that.

It can, but not necessarily.

And the great thing about each generation is it builds on the previous one.

So all of the technology and learnings that went into the previous generation are applied.

And then, of course, all the new innovation.

And so we have had a pretty regular cadence of introduction of new platforms.

And, you know, I think one of the newer technologies

uh considerations that has come in as we uh particularly with g7 uh was the scale and just the equipment and how you modify your your lines to be able to build the new technology but we've gotten pretty good at that and so i'm very excited about the new innovations we've made both on the g8 technology but also in how we manufacture it that'll lead to being able to you know scale larger sort of broader populations

This end market is so large and there's so many people out there that could benefit.

And right now we estimate there's about 10 million people using CGM, but there's 600 million people with diabetes.

So there is a lot of opportunity.

And so it's on us to make sure we have a technology that can both

Showing 261–280 of 301 · page 14 of 16